(Cyclopropylmethyl)(methylsulfonyl)-(2-piperazinyl-phenyl)amine | 494783-46-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (Cyclopropylmethyl)(methylsulfonyl)-(2-piperazinyl-phenyl)amine
• 英文别名: N-(cyclopropylmethyl)-N-(2-piperazin-1-ylphenyl)methanesulfonamide
• CAS: 494783-46-9
• 化学式: C₁₅H₂₃N₃O₂S
• 分子量: 309.433
• InChiKey: MCCGMYFYRIPURL-UHFFFAOYSA-N

物化性质

• 沸点：
  477.3±55.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (Cyclopropylmethyl)(methylsulfonyl)-(2-piperazinyl-phenyl)amine 在 N-羟基-7-氮杂苯并三氮唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-2-(4-Chloro-benzyl)-1-{4-[2-(2-cyclopropyl-1-methanesulfonyl-ethyl)-phenyl]-piperazin-1-yl}-4-piperazin-1-yl-butane-1,4-dione
  参考文献：
  名称：

  Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core

  摘要：

  A novel series of piperazines appended to a succinamide backbone were synthesized and found to have a high affinity for the melanocortin-4 receptor (IC(50)s ranging from <0.1 to 200 nM). Both agonists and antagonists of MC4R were prepared by modifying the groups attached to the right-hand side of the succinamide. This series also exhibits a high level of selectivity (up to 7000-fold) over mouse MC1R and human MC3R. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.056
• 作为产物：
  描述：

  1-Boc-4-(2-氨基苯基)哌嗪 在 sodium hydride 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (Cyclopropylmethyl)(methylsulfonyl)-(2-piperazinyl-phenyl)amine
  参考文献：
  名称：

  Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides

  摘要：

  The biological activity for a set of melanocortin-4 receptor (MC4R) agonists containing a piperazine core with an ortho-substituted aryl sulfonamide is described. Compounds from this set had binding and functional activities at MC4R less than 30 nM. The most selective compound in this series was > 25,000-fold more potent at MC4R than MC3R, and 490-fold more potent at MC4R than MC5R. This compound also reduced food intake after oral dosing at 25, 50, and 100 mg kg(-1) in fasted mice. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.060

文献信息

• Substituted piperazines and methods of use
  申请人：——

  公开号：US20030220324A1

  公开（公告）日：2003-11-27

  Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选择的替代哌嗪化合物对于预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新型化合物、类似物、前药和其药用盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这些过程中有用的中间体。
• Substituted piperazinyl amides and methods of use
  申请人：Amgen Inc.

  公开号：US07115607B2

  公开（公告）日：2006-10-03

  Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  公式I中选择的取代哌嗪化合物对于预防和治疗肥胖症等疾病有效。本发明涵盖了新型化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗激活黑色素细胞受体相关的疾病和其他疾病或病情的方法。本发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
• US7115607B2
  申请人：——

  公开号：US7115607B2

  公开（公告）日：2006-10-03
• US7291619B2
  申请人：——

  公开号：US7291619B2

  公开（公告）日：2007-11-06
• US7560460B2
  申请人：——

  公开号：US7560460B2

  公开（公告）日：2009-07-14